Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.01
$13.00
$6.16
$16.73
$756.53M1.9913,615 shs525,408 shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$3.57
$4.88
$2.85
$7.98
$741.52M0.68853,806 shs3.55 million shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$12.01
$12.88
$10.03
$69.97
$191.45M1.67551,695 shs567,084 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$12.90
$11.01
$7.16
$14.27
$762.59M0.912.10 million shs1.95 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+2.67%+6.68%+86.69%+121.39%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
0.00%-7.27%-30.54%-38.24%+7.18%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
0.00%+5.81%-17.17%-19.93%-65.01%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.00%+1.98%+25.98%+39.76%+42.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.01
$13.00
$6.16
$16.73
$756.53M1.9913,615 shs525,408 shs
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$3.57
$4.88
$2.85
$7.98
$741.52M0.68853,806 shs3.55 million shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$12.01
$12.88
$10.03
$69.97
$191.45M1.67551,695 shs567,084 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$12.90
$11.01
$7.16
$14.27
$762.59M0.912.10 million shs1.95 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+2.67%+6.68%+86.69%+121.39%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
0.00%-7.27%-30.54%-38.24%+7.18%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
0.00%+5.81%-17.17%-19.93%-65.01%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.00%+1.98%+25.98%+39.76%+42.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.110.67% Upside
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
3.10
Buy$16.56363.74% Upside
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.50
Moderate Buy$22.0083.18% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.80
Moderate Buy$29.29127.02% Upside

Current Analyst Ratings Breakdown

Latest TNXP, ZVRA, CYRX, and IVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$25.00 ➝ $29.00
6/10/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$25.00 ➝ $35.00
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetBuy$24.00 ➝ $29.00
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingBuy
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingOutperform
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Reiterated RatingBuy$23.00 ➝ $27.00
6/9/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetMarket Outperform$18.00 ➝ $25.00
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingHold$13.00
6/8/2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Boost Price TargetOverweight$24.00 ➝ $34.00
6/3/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $20.00
(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$182.94M4.14N/AN/A$9.19 per share1.63
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
$5.07M146.26N/AN/A($0.22) per share-16.23
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$13.11M14.60N/AN/A$19.17 per share0.63
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$106.47M7.16$0.95 per share13.64$2.75 per share4.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.12N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$400.67MN/AN/AN/AN/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$83.23M$1.996.4813.58N/A101.58%51.49%28.86%8/11/2026 (Estimated)

Latest TNXP, ZVRA, CYRX, and IVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million
5/6/2026Q1 2026
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$0.06$0.18+$0.12$0.60$31.96 million$36.22 million
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
3/30/2026Q4 2025
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
-$0.18-$0.7480-$0.5680-$0.16$8.67 million$0.01 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
N/A
3.16
3.16
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
6.99
6.86
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/A
4.89
4.84

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
19.06%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
32.00%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.00%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Inventiva S.A. Sponsored ADR stock logo
IVA
Inventiva
100207.71 million141.24 millionNot Optionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
5015.94 million15.62 millionNot Optionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2059.12 million57.70 millionOptionable

Recent News About These Companies

Zevra Therapeutics: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.01 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$15.02 +0.02 (+0.10%)
As of 06/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Inventiva stock logo

Inventiva NASDAQ:IVA

$3.57 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$3.62 +0.05 (+1.34%)
As of 06/18/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$12.01 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$11.98 -0.03 (-0.25%)
As of 06/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$12.90 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$12.84 -0.06 (-0.50%)
As of 06/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.